CDKN2A and neoplasm: Genetic inactivation of p16INK4a following deletion or mutation of the gene encoding this structural inhibitor of CDK4/Cyclin D is one of the most frequent tumour suppressor mutations in human cancers and results in defective inhibition of CDK4.